Overview

ChangE From Any Systemic psoriasiS therapY to Raptiva

Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.
Phase:
Phase 4
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Antibodies
Antibodies, Monoclonal